SynthesisBMC infectious diseases2026
Prognostic value of immune-inflammation indexes for the clinical outcomes of HIV/AIDS: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hematological Profile and Outcomes in Newly Diagnosed Patients with HIV: A 12-Month Single-Centre Cohort Study.Viruses · 2026Article
- Interleukin-2-Mediated Engraftment of Human Peripheral Blood Mononuclear Cells in Immunodeficient Mice to Develop a Model of HIV Infection: New Criteria for Engraftment Monitoring.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe immune-inflammation indexes such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and prognostic nutritional index (PNI), are recognized bioindicators for inflammation during HIV/AIDS, making them valuable indicators for clinical practice. This study aims to comprehensively evaluate the predictive value of immune inflammatory markers (NLR, PLR, MLR, and PNI) for the prognosis of HIV/AIDS patients through a systematic review and meta-analysis.
methodsThis systematic review and meta-analysis was conducted under the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Embase, Cochrane Library, and Web of Science were thoroughly searched until July 31, 2025. The odds ratio (OR)/standard mean differences and 95% confidence interval (95% CI) were extracted. A random-effects model was selected to synthesize all data. The stability of results and potential sources of heterogeneity were explored through sensitivity and subgroup analyses.
resultsA total of 15 studies with 28,190 patients(mean age: 35.81 years; 67.72% male) were included. A higher NLR predicted a greater risk of mortality (OR: 2.01, 95% CI: 1.49–2.73, I2 = 57%) and cancer (OR: 1.27, 95% CI: 1.01–1.60, I2 = 40%) in people with HIV/AIDS. Subgroup analyses found that study design, sample size, region, age, CD4+T-cell count ≤ 350 cells/µL and cut-off value were the sources of heterogeneity in the prediction of mortality by NLR. AIDS-related cancer patients with high PLR values had a greater risk of cancer (OR: 1.28, 95% CI: 1.11–1.49, I2= 0%). In subgroup analyses, PLR > 150 predicted higher mortality risk (OR: 3.14, 95% CI: 1.03–9.56). Patients with higher MLR levels had a higher mortality rate (OR:1.83, 95% CI: 1.01–3.32, I2 = 0%) and a greater risk of tuberculosis (OR: 2.40, 95% CI: 1.07–5.41, I2 = 81%). Patients with lower PNI levels had a greater risk of cancer (OR: 1.14, 95% CI: 1.03–1.25, I2 = 61%).
conclusionNLR, PLR, MLR, and PNI are reliable and valuable biomarkers for predicting the prognosis of adult patients with HIV/AIDS. Integrating these indicators into clinical practice may help improve risk stratification for mortality and complications, especially in resource-limited settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.